What is HC Wainwright's Estimate for VRDN Q1 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - HC Wainwright issued their Q1 2026 EPS estimates for shares of Viridian Therapeutics in a research note issued on Wednesday, May 7th. HC Wainwright analyst D. Tsao expects that the company will earn ($1.02) per share for the quarter. HC Wainwright has a "Buy" rating and a $34.00 price objective on the stock. The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share. HC Wainwright also issued estimates for Viridian Therapeutics' Q3 2026 earnings at ($1.05) EPS and Q4 2026 earnings at ($0.95) EPS.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. The firm had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm's revenue was up .0% compared to the same quarter last year.

A number of other equities analysts have also recently weighed in on VRDN. Needham & Company LLC dropped their price target on Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating on the stock in a research note on Wednesday. JMP Securities dropped their target price on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research report on Wednesday. The Goldman Sachs Group cut their price target on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday. Finally, Royal Bank of Canada decreased their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research note on Wednesday. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, Viridian Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $36.70.

Viridian Therapeutics Price Performance

Shares of NASDAQ VRDN traded down $0.24 during mid-day trading on Thursday, reaching $12.54. The company had a trading volume of 655,726 shares, compared to its average volume of 1,197,164. The company has a 50-day moving average price of $13.71 and a two-hundred day moving average price of $17.49. The stock has a market cap of $1.02 billion, a PE ratio of -2.91 and a beta of 0.57. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics has a 1-year low of $9.90 and a 1-year high of $27.20.

Hedge Funds Weigh In On Viridian Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. R Squared Ltd bought a new stake in shares of Viridian Therapeutics in the 4th quarter worth approximately $26,000. Amalgamated Bank raised its holdings in shares of Viridian Therapeutics by 49.7% in the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company's stock worth $34,000 after buying an additional 840 shares in the last quarter. Foresite Capital Management VI LLC bought a new position in shares of Viridian Therapeutics during the 4th quarter worth approximately $38,000. AlphaQuest LLC boosted its stake in Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after buying an additional 1,519 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in Viridian Therapeutics by 3,892.9% in the first quarter. GAMMA Investing LLC now owns 8,425 shares of the company's stock valued at $114,000 after acquiring an additional 8,214 shares during the period.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.